

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/767,260	01/30/2004	Yoshihide Matsuo	04853.0108	6256
22852	7590 06/21/200	5	EXAMINER	
FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER LLP 901 NEW YORK AVENUE, NW			SRIVASTAVA	, KAILASH C
			ART UNIT	PAPER NUMBER
WASHINGTON, DC 20001-4413		1655		

DATE MAILED: 06/21/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	
	10/767,260	MATSUO, YOSHIHIDE	
Office Action Summary	Examiner	Art Unit	
	Dr. Kailash C. Srivastava	1655	
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address	
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim will apply and will expire SIX (6) MONTHS from the cause the application to become ABANDONEI	l. ely filed the mailing date of this communication. O (35 U.S.C. § 133).	
Status			
1) ■ Responsive to communication(s) filed on 30 Ja 2a) ■ This action is FINAL. 2b) ■ This 3) ■ Since this application is in condition for allowar closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro		
Disposition of Claims			
4) ☐ Claim(s) 1-14 is/are pending in the application. 4a) Of the above claim(s) is/are withdray 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) 1-14 are subject to restriction and/or expending the subject to restriction and subject to restriction and/or expending the subject to restriction and subject to restriction and/or expending the subject to restriction and subject to re	vn from consideration.		
Application Papers			
9) The specification is objected to by the Examine		-	
10) The drawing(s) filed on is/are: a) acceptance and acceptance and acceptance are acceptanced as a consistency and acceptance are acceptanced as a consistency acceptance and acceptance are acceptanced as a consistency acceptance acceptance are acceptance acceptance and acceptance acceptance acceptance acceptance are acceptance acce			
Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct			
11) The oath or declaration is objected to by the Ex			
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priority documents application from the International Bureau * See the attached detailed Office action for a list	s have been received. s have been received in Applicati rity documents have been receive u (PCT Rule 17.2(a)).	on No ed in this National Stage	
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Do 5) Notice of Informal F 6) Other:		

DETAILED ACTION

1. Your application under prosecution at the United States Patent and Trademark Office (i.e., USPTO) has been assigned to Art Unit 1655. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Examiner Kailash C. Srivastava in Art Unit 1655.

Claims Status

2. Claims 1-14 are pending.

Election/Restriction

- 3. Restriction to one of the following inventions is required under 35 U.S.C. §121:
 - Group I comprising Claims 1-4 drawn to a colorless compound from FERM BP-8417, said compound having a molecular weight of 457, classified under Class 435, Subclass 119, for example.
 - Group II—Encompassing Claims 5-6 drawn to a colorless compound having a structure different than the organic c compound claimed in invention I, classified under Class 435, Subclass 122, for example.
 - Group III- Encompassing Claims 7-10 drawn to a method to prepare a composition via culturing FERM BP-8417, classified under Class 435, Subclass 127, for example.
 - Group IV- Encompassing Claims 7-10 drawn to a Culture medium for algae comprising compounds from Group I or Group II invention, classified under Class 435, subclass 257.1, for example.
 - Group V- Encompassing Claim 13 drawn to a mono- di- or trimethylated compound obtained by reacting the compound of Group I invention with trimethylsilyldiazomethane, classified under Class 435, subclass 156, for example.
 - Group VI- Encompassing Claim 14 drawn to a compound obtained by reacting the compound of Group V invention with sodium borohydrate, classified under Class 435, subclass? for example.

Inventions are Independent Or Distinct

4. The inventions are distinct, each from the other because of the following reasons:

Inventions in Groups I-II and V-VI are related to each other as sub-combinations disclosed as usable together in a single combination. The sub-combinations are distinct from each other if they are shown to be separately usable. In the instant case, an invention in Groups I-II has separate utility. For example invention in Group II has a completely different structure than that of the compound in Group I and compounds of Groups V and VI despite being prepared from inventive compounds in Group I have a structure and composition than that of the compounds in inventive Groups I-II. Therefore, the composition of each one of inventions encompassing claims in each of Groups I-II and V-VI can function independent of each other as a mere supplement to any composition, while composition in Group II would still function as a supplement to a growth medium to grow algae.

Inventions in Groups I-II are related to invention in Group III as products made and process of making said product. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case the claimed method to prepare said composition may also be used to prepare any chemical or a fermentation product (e.g., citric acid). Likewise, the claimed biological composition may also be prepped by other non-fermentation methods.

Inventions in Groups I-II are related to invention in Groups IV-VI as product and use thereof. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product [MPEP § 806.05(h)]. The product of inventive group IV could also be comprised of a fermentation/ enzymatic product or chemically synthesized compound (s) (e.g., tryptones or peptones or other growth factors) having morphogenic and growth accelerating properties said compound(s) being obtained from the market place where medium components for growing algae are obtained.

Method invention in Group III and composition inventions in Groups IV-VI are not connected in design, operation, and/or effect. These methods are independent since they are not disclosed as capable of use together, they have different modes of operation, they have different functions, and/or they have different effects. One would not have to practice the various methods at the same time to practice just one method alone.

The several inventions above are independent and distinct, each from the other. They have acquired a separate status in the art as a separate subject for inventive effect and require independent searches. The search for each one of the above inventions is not coextensive particularly with regard to the literature search. For example the strategy for searching the invention in Group I will require incorporation of only one structure and the chemical properties, whereas one in Group II would additionally require a different structure than that of invention of Group I. Likewise, the search strategy for the invention in Group III would require the key words with microbial name and fermentation aspects that will not be required to search any of the inventions in Groups I-II and IV-VI. Similarly different search strategies with different key words unique to inventions IV-VI will be required. Further, a reference that would anticipate the invention of one group would not necessarily anticipate or even make obvious another group. Finally the consideration for patentability is different in each case. Thus, it would be an undue burden to examine all of the above inventions in one application.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, and their recognized diverse subject matter, restriction for examination purposes as indicated is proper.

5. Applicants are advised that a reply to this requirement must include an identification of an invention elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicants will be entitled to consideration of additional claims which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR §1.141. Currently, Claims 1, 5, 7, 11, 13 and 14 are generic claims. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

- 6. Applicants are reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR §1.48(b). Any amendment of inventorship must be accompanied by a petition under 37 CFR §1.48(b) and by the fee required under 37 CFR §1.17(I).
- 7. The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. **Process claims that depend from or otherwise**

include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR §1.116; amendments submitted after allowance are governed by 37 CFR §1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR §1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai, In re Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Kailash C. Srivastava whose telephone number is (571) 272-0923. The examiner can normally be reached on Monday to Thursday from 7:30 A.M. to 6:00 P.M. (Eastern Standard or Daylight Savings Time).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Terry McKelvey, can be reached on (571)-272-0775 Monday through Friday between 08:30 AM and 5:00 PM. The fax phone number for the organization where this application or proceeding is assigned is (571)-273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding may be obtained from the Patent Application Information Retrieval (i.e., PAIR) system. Status information for the published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (i.e., EBC) at: (866)-217-9197 (toll-free). Alternatively, status inquiries should be directed to the receptionist whose telephone number is (703) 308-0196.

Kailash C. Srivastava, Ph.D.

Patent Examiner Art Unit <u>1651</u> (571) 272-0923

June 14, 2006

Raciones

RALPH GITOMER PRIMARY EXAMINER GROUP 1200